Talinolol's metabolism is influenced by the CYP2D6 enzyme, where genetic variations can lead to different metabolic rates affecting the drugâ€™s plasma levels and efficacy. Additionally, talinolol's interaction with ABCB1 and ABCC2 transporter proteins impacts its absorption and excretion, which are crucial in determining the drug's bioavailability and systemic exposure, ultimately affecting its effectiveness and safety.